| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study F Imbert-Bismut, V Ratziu, L Pieroni, F Charlotte, Y Benhamou, T Poynard The Lancet 357 (9262), 1069-1075, 2001 | 1980 | 2001 |
| Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients Y Benhamou, M Bochet, V Di Martino, F Charlotte, F Azria, A Coutellier, ... Hepatology 30 (4), 1054-1058, 1999 | 1630 | 1999 |
| Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. BJR Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD ... Ann Intern Med 163 (7), 1-13, 2015 | 689 | 2015 |
| A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis MN Investigators New England Journal of Medicine 390 (6), 497-509, 2024 | 675 | 2024 |
| Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications P Nahon, V Bourcier, R Layese, E Audureau, C Cagnot, P Marcellin, ... Gastroenterology 152 (1), 142-156. e2, 2017 | 625 | 2017 |
| Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis V Ratziu, L Bonyhay, V Di Martino, F Charlotte, L Cavallaro, ... Hepatology 35 (6), 1485-1493, 2002 | 614 | 2002 |
| Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)–NCT01514890 C Hézode, H Fontaine, C Dorival, D Larrey, F Zoulim, V Canva, ... Journal of hepatology 59 (3), 434-441, 2013 | 563 | 2013 |
| Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients Y Benhamou, M Bochet, V Thibault, V Di Martino, E Caumes, F Bricaire, ... Hepatology 30 (5), 1302-1306, 1999 | 546 | 1999 |
| A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. NS Group. N Engl J Med 385 (17), 1545-1558, 2021 | 519* | 2021 |
| Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: impact of protease inhibitor therapy Y Benhamou, V Di Martino, M Bochet, G Colombet, V Thibault, A Liou, ... Hepatology 34 (2), 283-287, 2001 | 512 | 2001 |
| Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B RP Myers, MH Tainturier, V Ratziu, A Piton, V Thibault, F Imbert-Bismut, ... Journal of hepatology 39 (2), 222-230, 2003 | 475 | 2003 |
| The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study V Di Martino, P Rufat, N Boyer, P Renard, S Matheron, V Le Moing, ... Hepatology 34 (6), 1193-1199, 2001 | 422 | 2001 |
| Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis Y Bacq, L Sentilhes, HB Reyes, A Glantz, J Kondrackiene, T Binder, ... Gastroenterology 143 (6), 1492-1501, 2012 | 365 | 2012 |
| Progression of liver fibrosis in women infected with hepatitis C: long‐term benefit of estrogen exposure VD Martino, P Lebray, RP Myers, E Pannier, V Paradis, F Charlotte, ... Hepatology 40 (6), 1426-1433, 2004 | 345 | 2004 |
| Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis C Hézode, H Fontaine, C Dorival, F Zoulim, D Larrey, V Canva, ... Gastroenterology 147 (1), 132-142. e4, 2014 | 336 | 2014 |
| Fatigue in patients with chronic hepatitis C T Poynard, P Cacoub, V Ratziu, RP Myers, MH Dezailles, A Mercadier, ... Journal of viral hepatitis 9 (4), 295-303, 2002 | 300 | 2002 |
| Fibrosis in patients with chronic hepatitis C: detection and significance T Poynard, V Ratziu, Y Benmanov, V Di Martino, P Bedossa, P Opolon Seminars in liver disease 20 (01), 0047-0056, 2000 | 271 | 2000 |
| Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B V Di Martino, T Thevenot, JF Colin, N Boyer, M Martinot, F Degos, ... Gastroenterology 123 (6), 1812-1822, 2002 | 265 | 2002 |
| Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs P Nahon, R Layese, V Bourcier, C Cagnot, P Marcellin, D Guyader, S Pol, ... Gastroenterology 155 (5), 1436-1450. e6, 2018 | 244 | 2018 |
| Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial T Thévenot, C Bureau, F Oberti, R Anty, A Louvet, A Plessier, M Rudler, ... Journal of hepatology 62 (4), 822-830, 2015 | 226 | 2015 |
Poynard TAPHP UPMC INSERM BioPredictiveایمیل تأیید شده در poynard.com
